KYNTRA BIO, INC. (KYNB)

6.87 0.04 (0.51%)

As of 2026-05-19 14:25:19 EST

Kyntra Bio, Inc. (formerly FibroGen, Inc.) is a biopharmaceutical company headquartered in San Francisco, California. Once regarded as a promising developer of innovative therapies for anemia and fibrotic diseases, with a market capitalization of roughly $4 billion in 2018–19, the company's value collapsed following late-stage trial failures, regulatory setbacks, and a data manipulation scandal. By 2026, Kyntra was mainly reduced to a single early-stage oncology drug candidate.

Traded asNasdaq: KYNB
ISINUS31572Q8814
CIK0000921299
LEI549300Q914ULWWY95822
EIN770357827
SectorBiotechnology
IndustryPharmaceutical Preparations
CEOThane Wettig
Employees34
Fiscal Year End1231
Address350 BAY STREET, SAN FRANCISCO, CA, 94133
Phone415-978-1200
Websitehttp://kyntrabio.com
Stock Quotes
trading_symbolregistrant_nametimepricechangepercentage_change
KYNBKYNTRA BIO, INC.2026-05-19 14:25:196.870.040.51
This is a preview of the latest data. Subscribe to access the full data.
Company Information
trading_symbolcentral_index_keyregistrant_nameisin_numberlei_numberein_numberexchangesic_codesic_descriptionfiscal_year_endstate_of_incorporationaddress_streetaddress_cityaddress_stateaddress_zip_codeaddress_countryaddress_country_codephone_numbermailing_addressbusiness_addressformer_nameindustryfounding_datechief_executive_officernumber_of_employeeswebsitemarket_capshares_issuedshares_outstandingdescriptionupdate_time
KYNB0000921299KYNTRA BIO, INC.US31572Q8814549300Q914ULWWY95822770357827Nasdaq2834Pharmaceutical Preparations1231DE350 BAY STREETSAN FRANCISCOCA94133UNITED STATESUS415-978-1200350 BAY STREET, SAN FRANCISCO, CA, 94133350 BAY STREET, SAN FRANCISCO, CA, 94133FIBROGEN INCBiotechnology1993Thane Wettig34http://kyntrabio.com21,000,0004,048,0004,048,112Kyntra Bio, Inc. (formerly FibroGen, Inc.) is a biopharmaceutical company headquartered in San Francisco, California. Once regarded as a promising developer of innovative therapies for anemia and fibrotic diseases, with a market capitalization of roughly $4 billion in 2018–19, the company's value collapsed following late-stage trial failures, regulatory setbacks, and a data manipulation scandal. By 2026, Kyntra was mainly reduced to a single early-stage oncology drug candidate.2026-05-14 19:44:44
This is a preview of the latest data. Subscribe to access the full data.
KYNB Stock Price (End-of-Day)
This is a preview of the latest data. Subscribe to access the full data.
KYNB Stock Price (1-Minute)
This is a preview of the latest data. Subscribe to access the full data.
Market Cap
Fiscal YearMarket CapChange In Market CapPercentage Change In Market CapShares OutstandingChange In Shares OutstandingPercentage Change In Shares Outstanding
202521,000,000-67,400,000-76.24434,046,827-96,870,129-95.9899
202488,400,000-173,100,000-66.195100,916,9562,145,7092.1724
2023261,500,000-713,600,000-73.182298,771,2474,588,3324.8717
This is a preview of the latest data. Subscribe to access the full data.
Employee Count
Fiscal YearEmployee Count
202534
This is a preview of the latest data. Subscribe to access the full data.
Income Statements
Fiscal Year202520242023
Revenue6,440,00029,621,000147,752,000
Cost Of Revenue556,00015,561,00018,848,000
Gross Profit5,884,00014,060,000128,904,000
Research And Development Expenses23,517,00095,692,000282,861,000
General And Administrative Expenses27,709,00049,330,000115,252,000
Operating Expenses52,335,000180,037,000429,567,000
Operating Income-45,895,000-150,416,000-281,815,000
Net Income183,452,000-47,579,000-284,232,000
Earnings Per Share Basic45.37-0.48-2.92
Earnings Per Share Diluted45.37-0.48-2.92
Weighted Average Shares Outstanding Basic4,043,000100,044,00097,303,000
Weighted Average Shares Outstanding Diluted4,043,000100,044,00097,303,000
This is a preview of the latest data. Subscribe to access the full data.
Balance Sheet Statements
Fiscal Year202520242023
Cash And Cash Equivalents47,872,00050,482,000113,688,000
Marketable Securities Current41,106,0000121,898,000
Accounts Receivable216,000481,00012,553,000
Inventories3,743,0003,155,00041,565,000
Non Trade Receivables———
Other Assets Current1,121,0001,139,0006,711,000
Total Assets Current99,073,000196,509,000331,559,000
Marketable Securities Non Current20,160,0000—
Property Plant And Equipment—013,126,000
Other Assets Non Current361,0001,405,0003,803,000
Total Assets Non Current20,521,00018,016,00091,970,000
Total Assets119,594,000214,525,000423,529,000
Accounts Payable3,745,0005,064,00017,960,000
Deferred Revenue5,314,00027,290,00012,740,000
Short Term Debt———
Other Liabilities Current20,183,00062,035,000172,891,000
Total Liabilities Current29,242,000133,306,000217,668,000
Long Term Debt—73,092,00071,934,000
Other Liabilities Non Current82,000822,0002,858,000
Total Liabilities Non Current85,877,000264,854,000368,060,000
Total Liabilities115,119,000398,160,000585,728,000
Common Stock1,012,0001,009,000988,000
Retained Earnings-1,706,047,000-1,889,499,000-1,841,920,000
Accumulated Other Comprehensive Income-2,182,000-5,732,000-6,875,000
Total Shareholders Equity-30,038,000-225,602,000-204,166,000
This is a preview of the latest data. Subscribe to access the full data.
Cash Flow Statements
Fiscal Year202520242023
Depreciation And Amortization713,0002,654,0009,518,000
Share Based Compensation Expense6,576,00025,215,00050,767,000
Other Non Cash Income Expense——1,000,000
Change In Accounts Receivable2,543,0006,737,000-3,433,000
Change In Inventories-5,362,000-22,284,0001,695,000
Change In Non Trade Receivables———
Change In Other Assets902,000-1,010,000-256,000
Change In Accounts Payable-27,654,00014,512,000-15,514,000
Change In Other Liabilities-53,497,000-93,790,000-49,778,000
Cash From Operating Activities-4,774,000-137,999,000-315,021,000
Purchases Of Marketable Securities61,158,0008,628,000251,830,000
Sales Of Marketable Securities0133,841,000400,621,000
Acquisition Of Property Plant And Equipment38,000266,0002,519,000
Acquisition Of Business———
Other Investing Activities———
Cash From Investing Activities35,419,000125,993,000153,657,000
Tax Withholding For Share Based Compensation69,000354,000237,000
Payments Of Dividends———
Issuance Of Common Stock0139,0003,731,000
Repurchase Of Common Stock———
Issuance Of Long Term Debt———
Repayment Of Long Term Debt—0336,000
Other Financing Activities———
Cash From Financing Activities-86,028,000-255,000122,749,000
Change In Cash-54,306,000-11,510,000-42,012,000
Cash At End Of Period47,872,00050,482,000113,688,000
Income Taxes Paid0——
Interest Paid7,830,00016,207,00054,000
This is a preview of the latest data. Subscribe to access the full data.
Key Metrics
Fiscal Year202520242023
Earnings Per Share45.37-0.48-2.92
Price To Earnings Ratio0.1935-27.5781-7.5882
Earnings Growth Rate-9,552.0833-83.5616-7.0064
Price Earnings To Growth Ratio-0.00.331.083
Book Value Per Share1.1069-1.8355-1.6669
Price To Book Ratio7.9324-7.2118-13.2923
Ebitda192,924,000-36,678,000-259,182,000
Enterprise Value—1,346,942,4502,114,237,222.5
Dividend Yield———
Dividend Payout Ratio———
Debt To Equity Ratio—-0.324-0.3523
Capital Expenditures—-10,472,0002,039,000
Free Cash Flow—-127,527,000-317,060,000
Return On Equity-6.10730.21091.3922
One Year Beta1.34121.48382.2482
Three Year Beta1.59271.45971.4299
Five Year Beta1.41591.35231.368
This is a preview of the latest data. Subscribe to access the full data.
Insider Transactions
Insider NameRelationship To IssuerTransaction DateAmount Of SecuritiesAcquired Or DisposedSecurities Owned Following Transaction
Wettig ThaneDirector, CEO2026-05-142,800A27,203
DeLucia DavidChief Financial Officer2026-02-0326,000A26,000
Wettig ThaneDirector, CEO2026-02-0360,000A60,000
This is a preview of the latest data. Subscribe to access the full data.
Institutional Holdings
Investor NamePeriod Of ReportMarket ValueAmount Of SecuritiesPrice Per Security
ADAR1 Capital Management, LLC2026-03-3170,98010,4696.78
ARMISTICE CAPITAL, LLC2026-03-312,712,000400,0006.78
Birchview Capital, LP2026-03-31152,99722,5666.78
GEODE CAPITAL MANAGEMENT, LLC2026-03-31311,93545,9986.7815
HARBOUR INVESTMENTS, INC.2026-03-311,3562006.78
This is a preview of the latest data. Subscribe to access the full data.
Mutual Fund Holdings
Registrant NamePeriod Of ReportFund NameFund SymbolAmount Of UnitsValue In UsdPercentage Value Compared To Assets
FIDELITY CONCORD STREET TRUST2026-02-28Fidelity Extended Market Index FundFSMAX21,198146,902.140.0004
FIDELITY CONCORD STREET TRUST2026-02-28Fidelity Nasdaq Composite Index FundFNCMX1,99113,797.630.0001
FIDELITY CONCORD STREET TRUST2026-02-28Fidelity Series Total Market Index FundFCFMX5,74439,805.920.0
FIDELITY CONCORD STREET TRUST2026-02-28Fidelity Total Market Index FundFSKAX7,00548,544.650.0
Advisors' Inner Circle Fund III2026-01-31I SharesKCXIX19156.340.0001
This is a preview of the latest data. Subscribe to access the full data.